Research Analysts’ Weekly Ratings Changes for Altimmune (ALT)

Several brokerages have updated their recommendations and price targets on shares of Altimmune (NASDAQ: ALT) in the last few weeks:

  • 11/14/2026 – Altimmune was downgraded by Wall Street Zen from “sell” to “strong sell”.
  • 11/13/2026 – Altimmune was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 11/13/2026 – Altimmune had its “market outperform” rating reaffirmed by Citigroup.
  • 11/13/2026 – Altimmune had its “buy” rating reaffirmed by B. Riley Financial.
  • 9/23/2026 – Altimmune had its “outperform” rating reaffirmed by Evercore.
  • 9/21/2026 – Altimmune had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Altimmune Trading Down 1.9%

Shares of NASDAQ ALT opened at $1.53 on Wednesday. The stock has a market cap of $297.72 million, a price-to-earnings ratio of -2.12 and a beta of 0.16. The business has a 50 day simple moving average of $2.51 and a 200 day simple moving average of $3.11. Altimmune, Inc. has a 52 week low of $1.50 and a 52 week high of $6.44. The company has a debt-to-equity ratio of 0.08, a quick ratio of 23.93 and a current ratio of 23.93.

Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). On average, research analysts predict that Altimmune, Inc. will post -0.60 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Altimmune news, CEO Jerome Durso bought 30,700 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was bought at an average cost of $1.62 per share, with a total value of $49,734.00. Following the completion of the transaction, the chief executive officer directly owned 93,200 shares of the company’s stock, valued at approximately $150,984. The trade was a 49.12% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased 50,700 shares of company stock valued at $82,334 over the last ninety days. Insiders own 1.60% of the company’s stock.

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

Read More

Receive News & Ratings for Altimmune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune Inc and related companies with MarketBeat.com's FREE daily email newsletter.